Enalapril in Heart Failure
Overview
Affiliations
Serum MK-422 and plasma angiotensin converting enzyme activity were measured during the introduction of enalapril therapy in eight patients with heart failure. In a second study of 16 patients, we recorded exercise tolerance, clinical status and haemodynamics before and after 12 weeks of placebo or enalapril treatment. Increasing doses of enalapril gave step-wise increments in serum MK-422. Plasma converting enzyme activity remained low for at least 24 h after each dose of enalapril (5, 10 and 20 mg). Compared to placebo patients (n = 8), those receiving enalapril (n = 8) tended to improve their exercise performance and clinical status, and showed a fall in right heart pressures after 12 weeks of treatment.
Agusti A, Bonet S, Arnau J, Vidal X, Laporte J Drug Saf. 2003; 26(12):895-908.
PMID: 12959631 DOI: 10.2165/00002018-200326120-00004.
Eccles M, Freemantle N, Mason J BMJ. 1998; 316(7141):1369-75.
PMID: 9563995 PMC: 1113074. DOI: 10.1136/bmj.316.7141.1369.
Webster M, Fitzpatrick M, Hamilton E, Nicholls M, Ikram H, Espiner E Drugs. 1985; 30 Suppl 1:74-81.
PMID: 2994990 DOI: 10.2165/00003495-198500301-00011.